Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin - Sabine Kayser; Chiara Sartor; Marlise R. Luskin; Jonathan Webster; Fabio Giglio; Nydia Panitz; Andrew M. Brunner; Matthias Fante; Christoph Lutz; Daniel Wolff; Anthony D. Ho; Mark J. Levis; et al. (Haematologica, 2022)